CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 194 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $6,205,365 | +1377.5% | 566,700 | +392.7% | 1.48% | +1802.6% |
| Q3 2021 | $420,000 | -41.4% | 115,015 | -17.8% | 0.08% | -69.9% |
| Q3 2019 | $717,000 | -90.2% | 140,000 | -74.5% | 0.26% | -87.2% |
| Q1 2019 | $7,304,000 | +28.0% | 550,000 | -24.1% | 2.02% | -5.0% |
| Q4 2018 | $5,705,000 | -26.2% | 725,000 | +3.9% | 2.13% | +8.2% |
| Q3 2018 | $7,735,000 | -17.4% | 698,100 | +0.1% | 1.97% | -18.8% |
| Q2 2018 | $9,360,000 | +8.4% | 697,500 | +4.9% | 2.42% | -1.9% |
| Q1 2018 | $8,638,000 | +41.2% | 665,000 | 0.0% | 2.47% | +26.1% |
| Q4 2017 | $6,118,000 | +14.2% | 665,000 | 0.0% | 1.96% | +3.4% |
| Q3 2017 | $5,356,000 | – | 665,000 | – | 1.89% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |